Multiple sclerosis shortens life by roughly six to ten years on average, but the way people die with MS is often misunderstood, even by those living with the disease. Most people do not die during a dramatic relapse or from MS attacking the brain directly. Instead, the causes tend to be complications that build quietly over years of disability: infections the body can no longer fight efficiently, pneumonia from swallowing difficulties, or cardiovascular problems. Understanding these patterns matters because many of these causes are, at least in theory, preventable or manageable. The stories behind MS deaths are less about sudden catastrophe and more about the slow accumulation of risk that advanced disability brings.
How Much Life Does MS Actually Take Away?
A population study tracking patients over six decades in western Norway found that the median life expectancy for all people with MS was about 74.7 years, compared with 81.8 years in the general population.1Journal of Neurology, Neurosurgery & Psychiatry. Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study That gap of roughly seven years is consistent with broader reviews estimating the reduction at six to ten years.2Neurology Bulletin. Impact of multiple sclerosis on life expectancy: a review But those numbers mask an important trend: the gap has been shrinking. In that same Norwegian study, the standardized mortality ratio dropped from 3.1 for people whose MS began between 1953 and 1974 down to 0.7 for those diagnosed from 1997 onward.3Journal of Neurology, Neurosurgery & Psychiatry. Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study A ratio below 1.0 means people diagnosed in the modern treatment era were dying at a rate no higher than the general population. That is a striking improvement.
A separate registry study in western Norway reinforced this, showing that people with relapsing-onset MS diagnosed between 2000 and 2019 had roughly half the mortality risk of those diagnosed in the 1990s.4PubMed Central. Mortality and cause of death in multiple sclerosis in western Norway 1950–2021: a registry-based linkage study The availability of disease-modifying therapies starting in the mid-1990s is almost certainly a major driver. People diagnosed before those drugs existed had mortality risks more than double those of later cohorts.5PubMed Central. Mortality and cause of death in multiple sclerosis in western Norway 1950–2021: a registry-based linkage study So the “death stories” of MS are, in part, a story of an era: outcomes today look far better than what patients faced a generation ago.
What People With MS Actually Die From
When MS is listed on a death certificate, the immediate cause of death is usually not the disease itself in the way a heart attack kills someone on the spot. In the Norwegian registry study, MS was recorded as the underlying cause of death in about half of all cases, but the conditions that actually ended life were overwhelmingly infections and circulatory diseases. Diseases of the circulatory system and cancers were the next most common underlying causes, accounting for about 15% each.6PubMed Central. Mortality and cause of death in multiple sclerosis in western Norway 1950–2021: a registry-based linkage study
A large U.S. population-based study that examined multiple causes listed on death certificates found a much more detailed picture. When MS was mentioned as a contributing factor, the likelihood of certain conditions being involved in the death rose dramatically. Urinary tract infections were about ten times more likely to play a role, aspiration pneumonia about seven times more likely, respiratory infections about three times more likely, and skin disease (typically pressure ulcers and their infections) about five times more likely.7PubMed Central. Multiple cause of death analysis in multiple sclerosis: A population-based study The researchers emphasized that all of these complications are tied to advanced disability and immobility, and are at least partly preventable.
This is the grim reality hidden behind the clinical statistics. A person who can no longer walk, turn in bed, or swallow safely is a person at high risk of developing a pressure sore that becomes infected, aspirating food into the lungs, or sitting with a catheter that seeds bacteria into the bloodstream. It is rarely one single event. It is the cascade of problems that advanced immobility creates.
Infections, Pneumonia, and the Cascade of Immobility
Infection is the single biggest contributor to MS-related death, and the mechanism is straightforward. As MS progresses and mobility declines, the body becomes vulnerable in ways that compound. A study of U.S. veterans found that people with MS faced nearly double the risk of fatal infections compared to matched controls without MS. The risk of serious urinary tract infections was more than four times higher, sepsis-related infections roughly two and a half times higher, and serious respiratory infections about 30% more common.8PubMed Central. Multiple Sclerosis and Risk of Infection-Related Hospitalization and Death in US Veterans
Swallowing difficulty, or dysphagia, is a particularly dangerous complication that does not get enough attention. It can occur at any stage of MS, though it becomes more common with age, disease duration, and progressive forms of the disease. The problem arises because MS can damage the nerve pathways that coordinate the complex act of swallowing, including connections running through the brainstem and cerebellum.9PubMed Central. Dysphagia in multiple sclerosis: pathophysiology, assessment, and management-an overview When swallowing goes wrong, food or liquid enters the airway instead of the stomach, leading to aspiration pneumonia. This is not a subtle process. The sevenfold increase in aspiration pneumonia on MS death certificates tells you how lethal it can be.10PubMed Central. Multiple cause of death analysis in multiple sclerosis: A population-based study
People often imagine MS deaths as dramatic neurological events. The reality is more prosaic and, in some ways, more tragic: a urinary tract infection that seeds the blood, a chest infection from silently aspirating saliva at night, a pressure ulcer that tunnels deep into tissue. These deaths are quiet, cumulative, and often happen in people who have been living with severe disability for years.
When MS Kills Quickly
There is, however, an exceedingly rare form of MS where death comes fast. Marburg variant MS is a fulminant, rapidly progressive form that can lead to death within weeks of the first symptoms.11PubMed Central. A Patient with Marburg’s Variant of Multiple Sclerosis Responded Well to Cyclophosphamide Unlike typical MS, which waxes and wanes over decades, Marburg variant MS is often a single, devastating monophasic attack that destroys large areas of brain tissue. Autopsy cases have documented severe disease courses ending in death within a year of the first clinical signs.12PubMed. The most fulminant course of the Marburg variant of multiple sclerosis-autopsy findings
Marburg variant MS is vanishingly uncommon, and some patients have responded to aggressive immunosuppressive treatment. But it is the closest thing MS has to an acute killer, and it underscores how wide the spectrum of the disease truly is. For most people with MS, the disease plays out over decades, not weeks. For a tiny handful, the timeline compresses catastrophically.
The Heart and the Autonomic Nervous System
Cardiovascular disease appears on MS death certificates at a rate that has prompted researchers to look more closely at the connection. MS can damage the autonomic nervous system, the network of nerves that regulates heart rate, blood pressure, and other functions you do not consciously control. A systematic review found that this cardiac autonomic dysfunction correlates with the underlying disease process of MS and can trigger serious cardiovascular complications that reduce life expectancy.13PubMed Central. Cardiac Autonomic Dysfunction in Multiple Sclerosis: A Systematic Review of Current Knowledge and Impact of Immunotherapies Some MS treatments, particularly fingolimod, can also affect heart rhythm when first started, adding a layer of treatment-related cardiac risk.
On top of the direct neurological connection, people with advanced MS are often sedentary, may be on medications that affect metabolism, and may have limited access to cardiovascular screening. These overlapping factors mean that heart disease is a meaningful contributor to MS mortality, even though it is rarely discussed in the same breath as relapses and lesions.
Suicide and the Psychological Weight of MS
One of the most painful aspects of MS mortality is the elevated rate of suicide. The standardized mortality ratio for suicide among people with MS is about twice that of the general population.14PubMed Central. Depression and Suicidality in Multiple Sclerosis: Red Flags, Management Strategies, and Ethical Considerations This is not simply a reaction to physical disability. Depression in MS has both psychological and neurobiological roots: the disease can directly damage brain circuits involved in mood regulation, and the inflammatory process itself appears to contribute to depressive symptoms.
Suicidal thoughts are particularly common around the time of diagnosis. A longitudinal study of people newly diagnosed with relapsing-remitting MS found that about 13% reported suicidal ideation at the time of diagnosis, and roughly 10% still reported it a year later.15PubMed. Suicidal ideation in the year following diagnosis of relapsing-remitting multiple sclerosis: A longitudinal perspective The researchers noted that suicidal thinking was present even among people with only mild depression, which means screening only for severe depression would miss many at-risk individuals. The period right after diagnosis, when the future feels most uncertain and frightening, appears to carry particular psychological danger.
When MS Treatments Themselves Carry Fatal Risk
Disease-modifying therapies have reshaped MS survival for the better, but some of the most effective drugs carry a small risk of a rare and often fatal brain infection called progressive multifocal leukoencephalopathy, or PML. PML is caused by a common virus that normally stays dormant but can reactivate when the immune system is suppressed. Several MS medications have been linked to PML cases, most prominently natalizumab, along with fingolimod and dimethyl fumarate.16PubMed. Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis
Natalizumab has received the most attention because its PML risk, while still small in absolute terms, is the highest among MS drugs. As of late 2018, over 800 cases of PML associated with natalizumab had been reported worldwide. In Sweden, where risk monitoring has been particularly rigorous, the estimated incidence was about 0.7 per 1,000 person-years of treatment, compared with a global estimate of roughly 4 per 1,000 person-years.17PubMed. Reduction of the risk of PML in natalizumab treated MS patients in Sweden: An effect of improved PML risk surveillance That difference highlights how active surveillance and timely drug discontinuation can reduce the risk substantially. PML is a genuine concern, but it is also a manageable one when patients and doctors monitor for it vigilantly.
Who Dies Earlier and Why Disparities Matter
MS mortality does not fall evenly across the population. In the United States, a study of MS death records from 1999 to 2015 confirmed the expected pattern that white people and women are more likely to be diagnosed with and die from MS. But Black Americans with MS died at younger ages and showed more steeply increasing mortality trends over the study period.18Neuroepidemiology. Multiple Sclerosis Mortality by Race/Ethnicity, Age, Sex, and Time Period in the United States, 1999–2015 This suggests that the burden of MS weighs more heavily on Black Americans in ways that go beyond the disease’s biology, likely reflecting differences in access to care, earlier and more aggressive disease in some individuals, and disparities in the management of complications.
Socioeconomic status tells a similar story. A nationwide study in France found a clear gradient for people with relapsing-onset MS: those from more economically deprived backgrounds had substantially higher excess mortality. After thirty years of disease, the gap in survival between the least and most deprived groups was about 17 percentage points for men and 12 percentage points for women.19The Lancet Regional Health – Europe. Socio-economic status and excess mortality in multiple sclerosis: a nationwide observational cohort study Poverty does not just make living with MS harder. It makes dying from it come sooner.
Children Diagnosed With MS Face a Different Timeline
About 3% to 5% of MS cases begin in childhood or adolescence. These patients tend to have a more inflammatory disease with frequent relapses early on, and there is a common reassurance that pediatric-onset MS progresses more slowly than adult-onset disease. That is true in a narrow sense: the pace of reaching significant disability milestones is somewhat slower per year. But because the clock starts so much earlier, children with MS reach those milestones at younger ages overall. A large study found that the median time to reach moderate disability was about 28 years for those diagnosed as children, compared with about 33 years for those diagnosed as adults.20JAMA Neurology. Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis That means pediatric-onset patients are hitting wheelchair-level disability, on average, in their early to mid-forties rather than their fifties or sixties. The downstream mortality implications of reaching advanced disability that young are significant, since all the infection and immobility risks described earlier kick in earlier.
What Families Go Through
The stories of MS deaths are not just about the person with the disease. Caregivers, most often spouses, parents, or adult children, carry an enormous psychological and physical burden that intensifies as the disease advances. A qualitative study asked caregivers to describe their burden using metaphors. Responses ranged from “an endless labyrinth” to choosing the color grey for tiredness, to one caregiver calling the situation “disastrous” and saying the family had been destroyed.21PLoS ONE. Burden and resources in caregivers of people with multiple sclerosis: A qualitative study A recurring theme was the fear of what happens when the caregiver themselves becomes ill or dies: “As long as I can, I will assist my child, because I’m his parent, but if I get sick, when I am old, and die, who will stay with him and take care of him?”22PLoS ONE. Burden and resources in caregivers of people with multiple sclerosis: A qualitative study
The loneliness and isolation that caregivers describe is compounded by the fact that MS can continue for decades. Unlike caring for someone with a rapidly terminal cancer, MS caregiving can stretch across twenty or thirty years, with periods of stability interrupted by unpredictable crises. That chronicity wears people down in ways that acute grief does not.
Palliative Care and the Gap That Persists
For a disease that kills through slow, progressive disability, MS is surprisingly underserved by palliative care. Palliative care is not the same as hospice: it focuses on symptom management, quality of life, and emotional support at any stage of a serious illness, not just the final weeks. Yet surveys of neurologists have found that many do not deal with end-of-life care issues in MS, and misunderstandings about what palliative care actually involves remain common among specialists.23PubMed. Palliative care in patients with severe multiple sclerosis: two case reports and a survey among German MS neurologists Because MS has a fluctuating, unpredictable trajectory rather than the steady decline of many cancers, it has historically not been seen as a disease that “belongs” in palliative care.24PubMed. Palliative care in progressive multiple sclerosis
This gap means that many people with advanced MS and their families are left to navigate pain management, breathing difficulties, feeding decisions, and end-of-life planning without the structured support that palliative teams provide. A qualitative study of people living with severe MS found that more than a third had done some form of advance planning, such as designating someone to make health decisions on their behalf or signing orders to refuse resuscitation, but many were not even familiar with the concept of advance care planning.25PLoS ONE. “I wanna live and not think about the future” what place for advance care planning for people living with severe multiple sclerosis and their families? A qualitative study
A realist review of the literature on advance care planning in MS identified several psychological factors that make these conversations difficult. Accepting that MS is a life-limiting illness is a prerequisite for seeing advance planning as relevant, and many people resist that framing for understandable reasons. The disease’s long, uncertain trajectory, with years of relative stability punctuated by sudden worsening, makes it hard to know when “the time” is to have these discussions. Health professionals often lack the advanced communication skills to initiate them.26PLoS ONE. A realist review of advance care planning for people with multiple sclerosis and their families
Medical Aid in Dying and MS
In countries and jurisdictions where euthanasia or medical assistance in dying is legal, MS is among the neurological conditions that most frequently motivate requests. A systematic review found that the ratio of euthanasia requests to total MS cases is higher than for many other diseases.27NeurologÃa (English Edition). Euthanasia and assisted suicide in neurological diseases: a systematic review This does not mean most people with MS seek this option, but it reflects the severity of suffering that advanced MS can entail and the value people place on autonomy as their bodies fail them.
A qualitative study asked people living with MS how they felt about medical assistance in dying under different hypothetical scenarios. The most commonly endorsed reasons for considering it were unbearable pain, the need for continuous care, and the perception of being a burden to others. Fewer participants said that losing pleasurable activities or changing living arrangements alone would prompt consideration.28Journal of Palliative Care / Institutional Repository. Navigating End-of-Life Choices: Perspectives of Individuals Living with Multiple Sclerosis on Medical Assistance in Dying in Various Hypothetical Situations The reasoning behind these choices revolved around shifting identity, guilt about burdening loved ones, and concern about the care available to family members after their death. For many, the desire for control over the end was inseparable from the experience of having lost control over everything else.
These conversations remain fraught. The overlap between suicidal ideation driven by treatable depression and a considered wish for an autonomous death is real and difficult to navigate. But ignoring the topic does not make it go away, and the research suggests that people with MS want to be able to discuss these options openly with their care teams, whether or not they ultimately pursue them.